CD8+ CTLs were essential anti-tumor effector cells in mice treated with the anti-CD4/anti-PD-1 mAb combination as CD8+ T cell depletion in vivo completely abrogated the effect of the combined immunotherapy. This evidence concerns the gene CD8A and neoplasm.